thalidomide has been researched along with Angiohemophilia in 7 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to present a new case on the successful use of thalidomide in a patient with acquired von Willebrand syndrome and recurrent angiodysplasia-related GI bleedings, and to conduct a literature review on the use of thalidomide in patients with GI angiodysplasia." | 8.91 | Thalidomide for treatment of gastrointestinal bleedings due to angiodysplasia: a case report in acquired von Willebrand syndrome and review of the literature. ( Engelen, ET; Schutgens, RE; van Galen, KP, 2015) |
| " Thalidomide has emerged as a promising medical strategy in angiodysplasia-related bleeding." | 8.91 | Thalidomide in angiodysplasia-related bleeding. ( Boey, JP; Hahn, U; McRae, SJ; Sagheer, S, 2015) |
| "Lenalidomide is a thalidomide analog with anti-angiogenic properties." | 5.48 | Lenalidomide as a novel therapy for gastrointestinal angiodysplasia in von Willebrand disease. ( Bull-Henry, K; Kessler, CM; Khatri, NV; Kohli, DR; Patel, B; Solomon, SS, 2018) |
| "An 80-year-old man with von Willebrand's disease was admitted with severe melaena." | 5.33 | Thalidomide as treatment for digestive tract angiodysplasias. ( Brouwer, RE; Heidt, J; Langers, AM; van der Meer, FJ, 2006) |
| "The aim of this study was to present a new case on the successful use of thalidomide in a patient with acquired von Willebrand syndrome and recurrent angiodysplasia-related GI bleedings, and to conduct a literature review on the use of thalidomide in patients with GI angiodysplasia." | 4.91 | Thalidomide for treatment of gastrointestinal bleedings due to angiodysplasia: a case report in acquired von Willebrand syndrome and review of the literature. ( Engelen, ET; Schutgens, RE; van Galen, KP, 2015) |
| " Thalidomide has emerged as a promising medical strategy in angiodysplasia-related bleeding." | 4.91 | Thalidomide in angiodysplasia-related bleeding. ( Boey, JP; Hahn, U; McRae, SJ; Sagheer, S, 2015) |
| "Lenalidomide is a thalidomide analog with anti-angiogenic properties." | 1.48 | Lenalidomide as a novel therapy for gastrointestinal angiodysplasia in von Willebrand disease. ( Bull-Henry, K; Kessler, CM; Khatri, NV; Kohli, DR; Patel, B; Solomon, SS, 2018) |
| "Lenalidomide is a potential treatment option for refractory bleeding in AVWS secondary to MG." | 1.43 | Lenalidomide as a novel treatment for refractory acquired von Willebrand syndrome associated with monoclonal gammopathy. ( Brophy, TM; Browne, PV; Hayden, PJ; Lavin, M; O'Connell, N; O'Donnell, JS; O'Sullivan, JM; Rawley, O; Ryan, K, 2016) |
| "An 80-year-old man with von Willebrand's disease was admitted with severe melaena." | 1.33 | Thalidomide as treatment for digestive tract angiodysplasias. ( Brouwer, RE; Heidt, J; Langers, AM; van der Meer, FJ, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Khatri, NV | 1 |
| Patel, B | 1 |
| Kohli, DR | 1 |
| Solomon, SS | 1 |
| Bull-Henry, K | 1 |
| Kessler, CM | 1 |
| Engelen, ET | 1 |
| van Galen, KP | 1 |
| Schutgens, RE | 1 |
| Boey, JP | 1 |
| Hahn, U | 1 |
| Sagheer, S | 1 |
| McRae, SJ | 1 |
| Lavin, M | 1 |
| Brophy, TM | 1 |
| Rawley, O | 1 |
| O'Sullivan, JM | 1 |
| Hayden, PJ | 1 |
| Browne, PV | 1 |
| Ryan, K | 1 |
| O'Connell, N | 1 |
| O'Donnell, JS | 1 |
| Ouyang, HY | 1 |
| Yu, ZJ | 1 |
| Yin, J | 1 |
| Zhao, XJ | 1 |
| Wang, ZY | 1 |
| Zhang, W | 1 |
| Ma, ZN | 1 |
| Su, J | 1 |
| Bai, X | 1 |
| Ruan, CG | 1 |
| Hirri, HM | 1 |
| Green, PJ | 1 |
| Lindsay, J | 1 |
| Heidt, J | 1 |
| Langers, AM | 1 |
| van der Meer, FJ | 1 |
| Brouwer, RE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Type 3 Von Willebrand International Registries Inhibitor Prospective Study[NCT02460458] | 265 participants (Actual) | Observational | 2012-11-05 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Measurement of Factor VIII (FVIII) Amidolytic Activity (FVIII:Am) in the blood through chromogenic test. Only patients with FVIII:Am less or equal to 5 IU/dL were considered for the analysis. (NCT02460458)
Timeframe: 12 months (confirmatory phase)
| Intervention | IU/dL (Mean) |
|---|---|
| Type 3 Von Willebrand's Disease (VWD3) | 1.63 |
Measurement of the amount of Factor VIII (FVIII) protein in the blood through FVIII:Ag test. Only patients with FVIII:Ag less or equal to 5 IU/dL were considered for the analysis. (NCT02460458)
Timeframe: 12 months (confirmatory phase)
| Intervention | IU/dL (Mean) |
|---|---|
| Type 3 Von Willebrand's Disease (VWD3) | 3.64 |
Measurement of the Factor VIII (FVIII) Procoagulant Activity (FVIII:C) in the blood through one-stage clotting test. Only patients with FVIII:C less or equal to 5 IU/dL were considered for the analysis. (NCT02460458)
Timeframe: 12 months (confirmatory phase)
| Intervention | IU/dL (Mean) |
|---|---|
| Type 3 Von Willebrand's Disease (VWD3) | 2.43 |
Measurement of Von Willebrand Factor (VWF) Propeptide levels in the blood through VWF Propeptide test. (NCT02460458)
Timeframe: 12 months (confirmatory phase)
| Intervention | IU/dL (Mean) |
|---|---|
| Type 3 Von Willebrand's Disease (VWD3) | 7.3 |
Measurement of the amount of Von Willebrand Factor (VWF) protein in the blood through Von Willebrand Factor Antigen (VWF:Ag) test. Only patients with VWF:Ag less or equal to 5 IU/dL were considered for the analysis. (NCT02460458)
Timeframe: 12 months (confirmatory phase)
| Intervention | IU/dL (Mean) |
|---|---|
| Type 3 Von Willebrand's Disease (VWD3) | 1.29 |
"Number of patients for who the following tests have been performed:~Hemoglobin (mmol/L), Hemagglutination Titer (HT) (%), Mean Corpuscular Volume (MVC) (fl), Leucocytes (E9/L), Neutrophils (%), Basophils (%), Eosinophils (%), Lymphocytes (%), Platelet Count (E9/L), Mean Platelet Volume (MPV) (fl), Prothrombin Time (sec), Partial Thromboplastin Time (PTT) (sec), Partial Thromboplastin Time Mix 50:50 (PTT mix 50:50) (sec), Ferritin (ug/l), Bleeding Time (min:sec), Closure Time (sec), Collagen/ADP (sec), Collagen/Epinephrine (sec); Factor VIII Procoagulant Activity (FVIII:C) (IU/mL), Von Willebrand Factor Ristocetin Cofactor (VWF:RCo) (IU/mL), Won Willebrand Factor Antigen (VWF:Ag) (IU/mL)." (NCT02460458)
Timeframe: 24 months (retrospective phase)
| Intervention | Participants (Count of Participants) |
|---|---|
| Type 3 Von Willebrand's Disease (VWD3) | 265 |
Evaluation of the titre of Anti-Von Willebrand Factor (anti-VWF) Antibodies through Bethesda Test. (NCT02460458)
Timeframe: 24 months (retrospective phase)
| Intervention | Participants (Count of Participants) |
|---|---|
| Type 3 Von Willebrand's Disease (VWD3) | 4 |
Record of any allergic and anaphylactic reactions occurred in the past due to the use of any Von Willebrand Factor (VWF) concentrate and the date of onset. (NCT02460458)
Timeframe: 24 months (retrospective phase)
| Intervention | Participants (Count of Participants) |
|---|---|
| Type 3 Von Willebrand's Disease (VWD3) | 41 |
Record of any product used during the retrospective phase (collected type of blood products/Von Willebrand Factor (VWF) concentrate, year of first exposure, units used). (NCT02460458)
Timeframe: 24 months (retrospective phase)
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Packed red cells | Cryoprecipitates | Fresh frozen plasma | Platelet concentrates | |
| Type 3 Von Willebrand's Disease (VWD3) | 24 | 123 | 10 | 1 |
3 reviews available for thalidomide and Angiohemophilia
| Article | Year |
|---|---|
Thalidomide for treatment of gastrointestinal bleedings due to angiodysplasia: a case report in acquired von Willebrand syndrome and review of the literature.
Topics: Aged; Angiodysplasia; Databases, Factual; Epistaxis; Female; Gastrointestinal Hemorrhage; Humans; Me | 2015 |
Thalidomide in angiodysplasia-related bleeding.
Topics: Aged; Aged, 80 and over; Angiodysplasia; Angiogenesis Inhibitors; Gastrointestinal Hemorrhage; Human | 2015 |
[Acquired von Willebrand syndrome in three patients and literature review].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Hemorrhage; Humans; Immunoglobulins, I | 2016 |
4 other studies available for thalidomide and Angiohemophilia
| Article | Year |
|---|---|
Lenalidomide as a novel therapy for gastrointestinal angiodysplasia in von Willebrand disease.
Topics: Aged; Angiodysplasia; Angiogenesis Inhibitors; Female; Humans; Lenalidomide; Male; Retrospective Stu | 2018 |
Lenalidomide as a novel treatment for refractory acquired von Willebrand syndrome associated with monoclonal gammopathy.
Topics: Aged; Anticoagulants; Drug Administration Schedule; Hemorrhage; Humans; Lenalidomide; Male; Middle A | 2016 |
Von Willebrand's disease and angiodysplasia treated with thalidomide.
Topics: Angiodysplasia; Angiogenesis Inhibitors; Humans; Male; Middle Aged; Thalidomide; Treatment Outcome; | 2006 |
Thalidomide as treatment for digestive tract angiodysplasias.
Topics: Aged, 80 and over; Angiodysplasia; Gastrointestinal Diseases; Gastrointestinal Hemorrhage; Humans; L | 2006 |